erdafitinib
16 abstracts
Abstract
Efficacy and safety of erdafitinib in pediatric patients with advanced solid tumors and FGFR alterations in the phase 2 RAGNAR trial.Org: Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), Memorial Sloan Kettering Cancer Center, FLENI,
Abstract
Efficacy and safety of erdafitinib in adults with breast cancer and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trial.Org: Hospital Privado de la Comunidad de Mar del Plata, Buenos Aires, Argentina, Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany, Vall d’Hebron Barcelona Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain, Department of Cancer Medicine and INSERM U981, Université Paris-Sud, Université Paris-Saclay, Gustave Roussy, Villejuif, France, Department of Oncology, AK Altona, Asklepios Tumourzentrum Hamburg, Hamburg, Germany,
Abstract
Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: Pooled analysis of RAGNAR and LUC2001 studies.Org: The People's Liberation Army 81 Hospital, University Hospital Gasthuisberg, Bristol Haematology and Oncology Centre, Statistics & Decision Sciences, Janssen China R&D Center, Chi-Mei Medical Center,
Abstract
FGFR3 alterations (FGFRalt) in patients (pts) who develop locally advanced or metastatic urothelial cancer (mUC), and their association with tumor subtype and clinical outcomes in pts treated with erdafitinib (erda) vs. pembrolizumab (pembro).Org: Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Greenberg Bladder Cancer Institute,
Abstract
A phase III randomized trial of eribulin (E) with gemcitabine (G) vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937 updated design.Org: Davis Comprehensive Cancer Center, Swog Gu Bladder Patient Advocate,
Abstract
SOGUG-NEOWIN: A phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in patients with cisplatin-ineligible muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations.Org: University of Sheffield, Université Paris-Sud, Université Paris-Saclay, Gustave Roussy Département d'Organisation du Parcours Patient, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy,
Abstract
FGFR3-mutated urothelial carcinoma of bladder and upper tract including ureter and renal pelvis: A comparative genomic profiling study.Org: Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Department of Medicine, Division of Hematology/Oncology, University of Washington, Fred Hutchinson Cancer Center, Department of Pathology, SUNY Upstate Medical University,
Abstract
Efficacy and safety of erdafitinib in adults with NSCLC and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trial.Org: Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Hospital Privado de la Comunidad de Mar del Plata, Buenos Aires, Argentina, Department of Cancer Medicine, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
Erdafitinb in patients with FGFR-altered tumors: Results from the NCI-COG Pediatric MATCH trial arm B (APEC1621B).Org: Weill Cornell Medicine, New York, NY, MD Anderson Cancer Center, Houston, TX, National Cancer Institute, Rockville, MD, Children's Oncology Group, Monrovia, CA, Texas Children's Cancer and Hematology Center, Houston, TX,
Abstract
Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).Org: Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan, Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, Medical Oncology Department, Institut de Cancérologie du Gard - CHU Caremeau, Nimes, France, Department of Medical Oncology, Centre Eugene Marquis, Rennes, France, Seoul National University Hospital, Seoul, Korea, Republic of (South),
Abstract
Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study.Org: Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London, United Kingdom, Department of Urology, Chonnam National University Medical School, Gwangju, South Korea, Janssen Research & Development, Spring House, PA, Gustave Roussy and Paris Saclay University, Villejuif, France, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
An in-progress phase 2 window of opportunity (WOO) trial of targeted therapy with erdafitinib for patients with recurrent FGFR3-altered non–muscle-invasive bladder cancer (NMIBC).Org: Memorial Sloan Kettering Cancer Center,
Abstract
Evaluating the use of circulating tumor DNA (ctDNA) in patients with urothelial cancer in the context of FGFR-targeted therapy.Org: Department of Medical Oncology, BC Cancer-Vancouver Centre, Vancouver, BC, Canada, Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada, Department of Medical Oncology, BC Cancer-Victoria Centre, Victoria, BC, Canada, Department of Medical Oncology, BC Cancer-Surrey Centre, Surrey, BC, Canada, Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada,
Abstract
Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary analysis.Org: Janssen Research & Development, Beerse, PA, Belgium, Janssen Research & Development, Shanghai City, China, Janssen Research & Development, Spring House, PA,
Abstract
A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.Org: SWOG Statistics and Data Management Center, Seattle, WA, University of California Davis Comprehensive Cancer Center, Fred Hutchinson Cancer Research Center, SWOG Cancer Research Network, Baylor College of Medicine,
Abstract
Clinical characteristics and treatment outcome of patients with advanced non-small-cell lung cancer (NSCLC) and FGFR fusions.Org: University of Cologne, University Hospital Cologne Center for Integrated Oncology, Institute for Pathology, Department of Translational Genomics, Network Genomic Medicine,